TROPION-Lung17 trial: what clinicians have said so far
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- NCT07291037 ↗
- Recruiting
- AstraZeneca
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on TROPION-Lung17 (datopotamab deruxtecan in TROP2-positive advanced/metastatic non-squamous NSCLC without actionable genomic alterations) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TROPION-Lung17 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built | |
| 2 YouTube videos, typically up to 9 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Datopotamab deruxtecan (Dato-DXd); Docetaxel
- Arms
- Arm A: Datopotamab deruxtecan (Dato-DXd) monotherapy · Experimental
- Arm B: Docetaxel monotherapy · Active comparator
- Enrollment
- 400 (estimated)
- Primary outcomes
- Progression-free survival (PFS)
- Overall survival (OS)
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Oct 31, 2025
- Primary completion
- Jan 29, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07291037 · updated Nov 10, 2026